HGF/c-Met comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
=== Latin America and Caribbean === Gustavo Petro, President of Colombia, initially suggested that any attack on Venezuela would equate to an attack on Latin America and the Caribbean, and thus Colombia's armed forces could support Venezuela; he later moderated his position. On 23 September, he addressed the UN General Assembly to call for a "criminal process" to be opened against Donald Trump for US strikes in the Caribbean. Colombia convened an extraordinary virtual meeting of the Community of Latin American and Caribbean States in September 2025, which concluded with an expression of "deep concern" over foreign intervention in the region. Over Guatemala's objection that procedures were not followed, the group issued a statement saying the region must remain a "Zone of Peace" based on "... the prohibition of the threat or use of force, the peaceful settlement of disputes, the promotion of dialogue and multilateralism, unrestricted respect for sovereignty and territorial integrity, non-interference in the internal affairs of States, and the inalienable right of peoples to self-determination." Guatemala's president Bernardo Arévalo said Guatemala was included in the list of 21 countries (of the 33 members) approving the text, although it did not sign, nor did Ecuador, Peru, Costa Rica, and El Salvador. In August, when the initial three ships were deployed, Prime Minister of Trinidad and Tobago Kamla Persad-Bissessar offered the US military access to her nation for the US to protect Guyana amid the Guyana–Venezuela crisis.
== List of notable total syntheses == Quinine total synthesis First synthesized by Robert Burns Woodward and William von Eggers Doering in 1944, this achievement was significant due to quinine's importance as an antimalarial drug. Strychnine total synthesis First synthesized by Robert Burns Woodward in 1954, this synthesis was a landmark achievement due to the molecule's structural complexity. Morphine: First synthesized by Marshall D. Gates in 1952, with subsequent more efficient syntheses developed by other chemists, including Toshiaki Fukuyama in 2017. Cholesterol total synthesis Synthesized by Robert Burns Woodward in 1951, this was a significant achievement in steroid synthesis. Cortisone: Another notable steroid synthesis by Robert Burns Woodward in 1951. Lysergic acid: Synthesized by Robert Burns Woodward in 1954, this was an important precursor to LSD. Reserpine: Completed by Robert Burns Woodward in 1956, this synthesis was notable for its complexity and the molecule's importance as an antihypertensive drug. Chlorophyll: Synthesized by Robert Burns Woodward in 1960, this achievement was significant due to chlorophyll's crucial role in photosynthesis. Colchicine: Another notable synthesis by Robert Burns Woodward, completed in 1963. Prostaglandin F2α: Synthesized by E.J. Corey in 1969, this was an important achievement in the synthesis of prostaglandins. Vitamin B12 total synthesis Completed by Robert Burns Woodward and his team in 1972, this synthesis is considered one of the most complex ever achieved, involving over 100 steps.
=== Counterfeiting === In major re-export hubs like Singapore, Malaysia and Hong Kong, fish maw is frequently mislabeled as more expensive varieties of fish, due to high profit incentive and the high level of visual similarity between disparately priced species. HK Magazine in 2007 described two incidents of counterfeit fish maw in Hong Kong: one of dried rabbit ear, and the other of shoe rubber.
PCP is well known for its primary action on the NMDA receptor, an ionotropic glutamate receptor. As such, PCP is a non-competitive NMDA receptor antagonist. The role of NMDAR antagonism in the effect of PCP, ketamine, and related dissociative agents was first published in the early 1980s by David Lodge and colleagues. Other NMDA receptor antagonists include ketamine, tiletamine, dextromethorphan, nitrous oxide, and dizocilpine (MK-801). Research also indicates that PCP inhibits nicotinic acetylcholine receptors (nAChRs) among other mechanisms. Analogues of PCP exhibit varying potency at nACh receptors and NMDA receptors. Findings demonstrate that presynaptic nAChRs and NMDA receptor interactions influence the postsynaptic maturation of glutamatergic synapses and consequently impact synaptic development and plasticity in the brain. These effects can lead to inhibition of excitatory glutamate activity in certain brain regions such as the hippocampus and cerebellum thus potentially leading to memory loss as one of the effects of prolonged use. Acute effects on the cerebellum manifest as changes in blood pressure, breathing rate, pulse rate, and loss of muscular coordination during intoxication. PCP, like ketamine, also acts as a potent dopamine D2High receptor partial agonist in rat brain homogenate and has affinity for the human cloned D2High receptor. This activity may be associated with some of the other more psychotic features of PCP intoxication, which is evidenced by the successful use of D2 receptor antagonists (such as haloperidol) in the treatment of PCP psychosis.
Sources: en.wikipedia.org
There have been increasing public calls for global collective action to address the threat, including a proposal for an international treaty on antimicrobial resistance. Further detail and attention is still needed to recognize and measure trends in resistance on the international level; the idea of a global tracking system has been suggested but implementation has yet to occur. A system of this nature would provide insight to areas of high resistance as well as information necessary for evaluating programs, introducing interventions and other changes made to fight or reverse antibiotic resistance.
=== 1970s === Recombinant DNA technology emerged in the 1970s, fundamentally transforming biomedical research. In 1972 and 1973, Paul Berg, Herbert Boyer, and Stanley Cohen developed techniques to cut and splice DNA molecules from different organisms, establishing the foundation of modern biotechnology. In 1975, Georges Kohler and Cesar Milstein developed hybridoma technology to produce monoclonal antibodies, creating highly specific tools for diagnostic assays and targeted therapies. The late 1970s also witnessed major public health milestones, including the global eradication of smallpox, certified by the World Health Organization in 1979, and the introduction of Fred Sanger's DNA sequencing method in 1977.
=== Mechanism === The cell membranes of bacteria are rich in acidic phospholipids, such as phosphatidylglycerol and cardiolipin. In contrast, the outer part of the membranes of plants and mammals is mainly composed of lipids without any net charges since most of the lipids with negatively charged headgroups are principally sequestered into the inner leaflet of the plasma membranes. Thus in the case of mammalian cells, the outer surfaces of the membranes are usually made of zwitterionic phosphatidylcholine and sphingomyelin, even though a small portion of the membrane's outer surfaces contain some negatively charged gangliosides. Therefore, the hydrophobic interaction between the hydrophobic face of amphipathic antimicrobial peptides and the zwitterionic phospholipids on the cell surface of mammalian cell membranes plays a major role in the formation of peptide-cell binding. Dual polarisation interferometry has been used in vitro to study and quantify the association to headgroup, insertion into the bilayer, pore formation and eventual disruption of the membrane.
Whether this panacea contained the traditional ingredients such as opium, myrrh and hemp, is not known. In the Middle East, theriac was known as Tiryaq, and makers of it were known as Tiryaqi. In medieval London, the preparation arrived on galleys from the Mediterranean, under the watchful eye of the Worshipful Company of Grocers. Theriac, the most expensive of medicaments, was called Venice treacle by the English apothecaries. At the time of the Black Death in the mid 14th century, Gentile da Foligno, who died of the plague in June 1348, recommended in his plague treatise that the theriac should have been aged at least a year. Children should not ingest it, he thought, but have it rubbed on them in a salve. In 1669, the famous French apothecary, Moyse Charas, published the formula for theriac, seeking to break the monopoly held by the Venetians at that time on the medication, thereby opening up the transfer of medical information.
Selenium disulfide, also known as selenium sulfide, is a chemical compound and medication used to treat seborrheic dermatitis, dandruff, and pityriasis versicolor. It is applied to the affected area as a lotion or shampoo. Symptoms frequently return if treatment is stopped. Side effects may include hair discoloration, skin irritation, and risk of systemic absorption and toxicity, among others. Use is not recommended in children less than 2–5 years old. Use in pregnancy or breastfeeding has not been studied. It consists of a mixture of inorganic covalent compounds having an approximate empirical formulas of SeS2. Selenium disulfide acts as a keratolytic and antifungal agent. Selenium disulfide was approved for medical use in the United States at least as early as 1951. It is on the World Health Organization's List of Essential Medicines. Selenium disulfide is available as a generic medication and over the counter.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.